TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23075703

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono‐LPV/r)
Number of subjects: 195

Group type: COMPARATOR
Intervention: tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Comparison of TWAUC HIV RNA between mono‐LPV/r and TDF/3TC/LPV/r
Number of subjects: 195
Study: 20574412

Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine (QHPV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 18664696

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) package for social anxiety
Number of subjects: 32

Group type: COMPARATOR
Intervention: Speech restructuring treatment alone
Number of subjects: 32
Study: 17057794

Group type: EXPERIMENTAL
Intervention: Mitomycin 0.25 mg/mL for 1 minute combined with temporary nasal tarsorrhaphy
Number of subjects: 20

Group type: COMPARATOR
Intervention: No mitomycin (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mitomycin group
Number of subjects: 20
Study: 12271112

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) self-help manual in six modules
Number of subjects: 117

Group type: COMPARATOR
Intervention: Waiting-list control group (WLC)
Number of subjects: 117
Study: 9932566

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 235
Study: 7792546

Group type: COMPARATOR
Intervention: Multimodal cognitive-behavioural treatments (MMCBT) with psychologist as a coach (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioural treatments (MMCBT) with direct psychologist contact (Group B)
Number of subjects: 66
Study: 1706610

Group type: EXPERIMENTAL
Intervention: LNH-84 regimen
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: T-cell ML
Number of subjects: 361

Group type: COMPARATOR
Intervention: B-cell ML
Number of subjects: 361
Study: 558548

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31298337

Group type: EXPERIMENTAL
Intervention: miR‐31 overexpression
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: miR‐31 restoration
Number of subjects: 54

Group type: COMPARATOR
Intervention: Declined miR‐31 expressions
Number of subjects: 54
Study: 28217935

Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study: 25442342

Group type: EXPERIMENTAL
Intervention: 1-mm GTV expansion
Number of subjects: 49

Group type: COMPARATOR
Intervention: 3-mm GTV expansion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 23063461

Group type: EXPERIMENTAL
Intervention: Attention-towards-positive (ATP) condition
Number of subjects: 37

Group type: COMPARATOR
Intervention: Attention-training-control (ATC) condition
Number of subjects: 37
Study: 21907058

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 19090439

Group type: EXPERIMENTAL
Intervention: Elective radical dissection of regional lymph nodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery, adjuvant treatment, or radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene-based control of metastases
Number of subjects: 0
Study: 16533348

Group type: EXPERIMENTAL
Intervention: Soccer-specific training program combining strength and technique exercises for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 14654574

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzymes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-II antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 0
Study: 10736077

Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untunnelled catheters
Number of subjects: 0
Study: 9168214

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (10 mg in 20 mL normal saline)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine (20 mL 0.5% with epinephrine)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (10 mg in 1 mL)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (20 mL IA normal saline + 1 mL SC normal saline)
Number of subjects: 112
Study: 8063651

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg/day; n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study: 2646850

Group type: EXPERIMENTAL
Intervention: Propofol (1.5-2.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopentone (3.0-4.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30
Study: 5460838

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Average Western diet (Control)
Number of subjects: 0
Study: 31721909

Group type: EXPERIMENTAL
Intervention: Shadow examiner
Number of subjects: 415

Group type: COMPARATOR
Intervention: Fixed examiner
Number of subjects: 415
Study: 28412598

Group type: EXPERIMENTAL
Intervention: Glottal fry
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Yawn-sigh
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no facilitating techniques)
Number of subjects: 36
Study: 25896115

Group type: EXPERIMENTAL
Intervention: LA Sprouts nutrition, cooking and gardening intervention
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Questionnaire scales
Number of subjects: 364
Study: 23993773

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsleep-related parent education (Comparison group)
Number of subjects: 40
Study: 21273301

Group type: EXPERIMENTAL
Intervention: Early treatment for Women with Alcohol Addiction (EWA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 200
Study: 20387350

Group type: EXPERIMENTAL
Intervention: Pethidine (0.35 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Doxapram (1.5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 30
Study: 17084675

Group type: EXPERIMENTAL
Intervention: Blastocyst embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cleavage-stage embryo transfer
Number of subjects: 0
Study: 15481278

Group type: EXPERIMENTAL
Intervention: S/FP 50/100 microg bd (n = 78)
Number of subjects: 150

Group type: COMPARATOR
Intervention: FP 100 microg bd (n = 72)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: S/FP
Number of subjects: 150
Study: 11529248

Group type: EXPERIMENTAL
Intervention: phVEGF165 gene transfer (1, 2, or 4 mg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 8963126

Group type: EXPERIMENTAL
Intervention: Modified staircase method (Landolt rings in eight positions, scaled by a factor 1.26, PC monitor with 1024 x 768 pixels, distance 4.5 m)
Number of subjects: 102

Group type: COMPARATOR
Intervention: DIN 58,220 method
Number of subjects: 102
Study: 1467377

Group type: EXPERIMENTAL
Intervention: Lithium (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study: 3909956

Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftazidime plus flucloxacillin
Number of subjects: 100
Study: 30485501

Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg for 7 days
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 28594629

Group type: EXPERIMENTAL
Intervention: Feedback to therapist and patient (FbTP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Feedback to therapist (FbT)
Number of subjects: 206

Group type: COMPARATOR
Intervention: No feedback (NFb)
Number of subjects: 206
Study: 26950661

Group type: EXPERIMENTAL
Intervention: Video-module instruction
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional lecture-demonstration approach
Number of subjects: 39
Study: 25628082

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control - Edgewise therapy only
Number of subjects: 90
Study: 22271197

Group type: EXPERIMENTAL
Intervention: Goal attainment scaling (GAS)
Number of subjects: 0
Study: 19289991

Group type: EXPERIMENTAL
Intervention: Machine Perfusion (MP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cold Storage (CS)
Number of subjects: 74
Study: 17766699

Group type: EXPERIMENTAL
Intervention: Rituximab alone (1000 mg administered intravenously on days 1 and 15)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 161

Group type: COMPARATOR
Intervention: Methotrexate alone (10-25 mg/wk)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab (all groups)
Number of subjects: 161
Study: 15077929

Group type: COMPARATOR
Intervention: CYFRA 21-1 in F0 expressed in ng/mg TP
Number of subjects: 93

Group type: COMPARATOR
Intervention: NSE in both fractions expressed in ng/mg TP
Number of subjects: 93

Group type: COMPARATOR
Intervention: SCC in F1 expressed in ng/mg TP
Number of subjects: 93

Group type: COMPARATOR
Intervention: TPA in F0 expressed in mU/mg TP
Number of subjects: 93

Group type: COMPARATOR
Intervention: TPS in both fractions expressed in mU/mg TP
Number of subjects: 93
Study: 11229833

Group type: EXPERIMENTAL
Intervention: 1 mg oral vitamin K1
Number of subjects: 109

Group type: COMPARATOR
Intervention: Discontinuation of one dose of acenocoumarine
Number of subjects: 109
Study: 9848299

Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (aPTT) before conception
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT) before conception
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Fibrinogen before conception
Number of subjects: 261
Study: 10634921

Group type: EXPERIMENTAL
Intervention: MCT 15 mmol/h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MCT 30 mmol/h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LCT 15 mmol/h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 2091170

Group type: EXPERIMENTAL
Intervention: Concurrent visual feedback during abduction of the fifth digit
Number of subjects: 39

Group type: COMPARATOR
Intervention: No feedback during thumb flexion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Feedback during thumb flexion
Number of subjects: 39
Study: 674355

Group type: EXPERIMENTAL
Intervention: Long acting neuroleptic drugs (fluphenazine decanoate, flupenthixol decanoate, fluspirilene)
Number of subjects: 97
Study: 31977446

Group type: EXPERIMENTAL
Intervention: Medial pivot TKA designs (Advance® II MP, GMK® Sphere, MRK, Evolution® MP, SAIPH®)
Number of subjects: 6310

Group type: EXPERIMENTAL
Intervention: Advance® II MP
Number of subjects: 6310

Group type: EXPERIMENTAL
Intervention: GMK® Sphere
Number of subjects: 6310

Group type: EXPERIMENTAL
Intervention: MRK
Number of subjects: 6310

Group type: EXPERIMENTAL
Intervention: Evolution® MP
Number of subjects: 6310

Group type: EXPERIMENTAL
Intervention: SAIPH®
Number of subjects: 6310

Group type: COMPARATOR
Intervention: Cruciate-retaining TKA designs
Number of subjects: 6310
Study: 30795731

Group type: EXPERIMENTAL
Intervention: Tiotropium (5 µg and 2.5 µg)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study: 27819215

Group type: EXPERIMENTAL
Intervention: Total dietary iron intake
Number of subjects: 7634

Group type: EXPERIMENTAL
Intervention: Animal dietary iron intake
Number of subjects: 7634

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 7634
Study: 25564476

Group type: EXPERIMENTAL
Intervention: glucagon‐like peptide (GLP‐1, 0.5 pmol·kg(‐1)·min(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: glucose‐dependent insulinotropic polypeptide (GIP, 1.5 pmol·kg(‐1)·min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline [control (CON)]
Number of subjects: 10
Study: 23388113

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9306

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 9306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study: 20939064

Group type: COMPARATOR
Intervention: Placebo compliance (high compliance defined as taking 80% or more of dispensed study medication)
Number of subjects: 3169

Group type: COMPARATOR
Intervention: Placebo compliance (high compliance)
Number of subjects: 3169
Study: 19335707

Group type: EXPERIMENTAL
Intervention: AZD6140 90 mg twice daily
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: AZD6140 180 mg twice daily
Number of subjects: 984

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: AZD6140 (combined groups)
Number of subjects: 984
Study: 16710253

Group type: EXPERIMENTAL
Intervention: Spirapril (stepwise antihypertensive therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypotensive drugs (standard treatment)
Number of subjects: 60
Study: 14724662

Group type: EXPERIMENTAL
Intervention: Low-cost telephone-based intervention
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Mail-based intervention
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Usual care intervention
Number of subjects: 1632
Study: 11344882

Group type: EXPERIMENTAL
Intervention: Counselors CARE (C‐CARE) (n = 150)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Coping and Support Training (CAST) (n = 155)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Usual-care control (n = 155)
Number of subjects: 460
Study: 9165168

Group type: EXPERIMENTAL
Intervention: Zatebradine (ULFS 49 CL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7955818

Group type: EXPERIMENTAL
Intervention: 1 mg mofegiline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 12 mg mofegiline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 24 mg mofegiline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3539524

Group type: EXPERIMENTAL
Intervention: Internal Jugular (IJ) route
Number of subjects: 66

Group type: COMPARATOR
Intervention: Subclavian (SC) route
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Second catheters placed over a guidewire
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Second catheters placed at a new site
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both IJ and SC routes
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Standard, sterile-insertion technique and catheter-maintenance protocol
Number of subjects: 66
Study: 29504258

Group type: EXPERIMENTAL
Intervention: Low-dose rhEPO for 2 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose rhEPO for 3 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28328396

Group type: EXPERIMENTAL
Intervention: m-Health intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study: 25052783

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control
Number of subjects: 285
Study: 22118014

Group type: EXPERIMENTAL
Intervention: Immediate non-occlusal implant loading
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early non-occlusal implant loading
Number of subjects: 60
Study: 21092504

Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography within 24 h of randomization)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography over 36 h after randomization)
Number of subjects: 815
Study: 18503257

Group type: EXPERIMENTAL
Intervention: High physical and chemical protection sunscreen (octocrylene, Parsol 1789, titanium dioxide, Mexoryl SX, Mexoryl XL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Physical opaque material
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nonprotected areas after UVR exposure
Number of subjects: 4
Study: 15681904

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy and adhesiolysis
Number of subjects: 72
Study: 12591757

Group type: EXPERIMENTAL
Intervention: Chronic dialysis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 61
Study: 10543576

Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Zinc-deficient diet
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cadmium exposure
Number of subjects: 125

Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 125
Study: 8823102

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heparin-coated surfaces
Number of subjects: 80

Group type: COMPARATOR
Intervention: Roller pump (uncoated circuits)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Roller pump (heparin-coated circuits)
Number of subjects: 80
Study: 1878235

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (Group 1, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with lidocaine 1% (Group 2, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% with fentanyl 50 micrograms in 10 ml of saline (Group 3, n = 15)
Number of subjects: 45
Study: 6308283

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31827320

Group type: EXPERIMENTAL
Intervention: Esketamine (0.5 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Racemic ketamine (1 mg/kg)
Number of subjects: 32
Study: 28398852

Group type: EXPERIMENTAL
Intervention: Peer intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Professional intervention
Number of subjects: 59
Study: 25683315

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin type A (BTX‐A) injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (NS) injection
Number of subjects: 16
Study: 24288083

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 12
Study: 22100966

Group type: COMPARATOR
Intervention: Diabetic (DM) group
Number of subjects: 147

Group type: COMPARATOR
Intervention: Impaired glucose tolerance (IGT) group
Number of subjects: 147

Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 147
Study: 20479765

Group type: EXPERIMENTAL
Intervention: Tesofensine (TE) 2.0 mg daily for 7 days followed by 1.0 mg daily for 7 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tesofensine (TE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study: 17401036

Group type: EXPERIMENTAL
Intervention: Brief psychoeducation plus 16 problem-solving group sessions
Number of subjects: 176

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 176
Study: 15865497

Group type: EXPERIMENTAL
Intervention: Cranberry juice (32 ounces/day of a beverage containing 27% cranberry juice)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 50
Study: 12028165

Group type: EXPERIMENTAL
Intervention: Oxybutynin group (2.5 mg daily to 5 mg three times a day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Behavioral training
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 105
Study: 9607264

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily with diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 60
Study: 7899538

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg bid)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2223370

Group type: EXPERIMENTAL
Intervention: morphine 0.1 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alfentanil 4.0 micrograms kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: combination of morphine and alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 40
Study: 75397

Group type: EXPERIMENTAL
Intervention: Supraliminal exposure to agoraphobic film
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subliminal exposure to agoraphobic film
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (blank screen)
Number of subjects: 15
Study: 31752751

Group type: EXPERIMENTAL
Intervention: 12-week intervention (weekly emails and social media posts)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 557
Study: 28974628

Group type: EXPERIMENTAL
Intervention: Cervical carotid dissection
Number of subjects: 295

Group type: COMPARATOR
Intervention: Cervical carotid atherosclerotic cause
Number of subjects: 295
Study: 25931799

Group type: EXPERIMENTAL
Intervention: Sevoflurane for inhalation anesthesia (I group)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Propofol for total intravenous anesthesia (T group)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 416
Study: 23663213

Group type: EXPERIMENTAL
Intervention: Treatment group (community program)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intention to exercise
Number of subjects: 69